APOTEX CORP. for APOTEX CORP.
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
S. 504, The Fair and Immediate Release of Generics Act, relating to market blockages caused by parked 180 day exclusivity periods S. 214, The Preserve Access to Affordable Pharmaceuticals Act, relating to the legality of "reverse payment" patent settlements Federal Trade Commission v. Actavis Supreme Court Case No. 12-416, relating to federal policy on "reverse payment" settlementsFederal legislation relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing Actelion Pharmaceutical LTD and Actelion Clinical Research Inc. V. Apotex Inc., Apotex Corp., and Roxane Laboratories Inc., United States District Court for the District of New Jersey, case 1:12-cvi-05743-NLH-AMD, relating to federal legislation regarding the provision of brand drug products by brand manufacturers to generic manufacturers for development testing Federal legisation relating to the establishment of a federal track and trace system for pharmaceuticals Federal policy relating to the adoption of an electronic labeling system for pharmaceuticals
Foreign entity interest: Aposherm Inc., Apotex Holdings Inc., Shermfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.